Halaven® (Eribulin Mesylate)
| Manufacturer: Eisai |
| General Information: Halaven® is typically
utilized in the treatment of patients with metastatic breast cancer
who have received at least two chemotherapy regimens. For
indication, dosing or other information, please refer to the
manufacture package insert. |
| |
|
Product |
Size |
NDC Number |
PI |
MSDS |
| Halaven® |
1mg/2mL |
62856-0389-01 |
PI |
MSDS
|
|
| |
| Clinical
Data: For any questions
or for further information
related to Halaven®
injection, clinical
pharmacology, additional
indications and usages,
contraindications, warnings,
precautions, adverse reactions,
dosage, administration and/or
storage of this product, please
contact
BDI Pharma or call 1-800-948-9834. |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |